ANO1 and prostate carcinoma: Furthermore, immunohistochemical analysis indicated that ANO1 was upregulated in human prostate cancer specimens, and this heightened expression corresponded with advanced clinical staging and more aggressive disease traits, pointing to its potential as a prognostic biomarker for prostate cancer [1].